After acquiring the Swedish Kibion company in 2016, Mayoly Spindler is pursuing its European development strategy and is setting up its pharmaceutical activities in Italy.

We are pleased to announce the creation of a new subsidiary of Mayoly Spindler: Mayoly Italia s.r.l. based in Milan and headed by Dr. Brenno Canovi.

The first product to be marketed by Mayoly Italia is FlorVis GG, a probiotic acquired in 2017, pending the launch of other products of the Mayoly Spindler portfolio in the coming months.

The opening of this subsidiary is a new step that allows our laboratory, committed in gastroenterology and in the development of probiotics, to consolidate its geographical footprint in Europe.